news, journals and articles from all over the world.
While researchers pursue scientific insights into the pancreatic cancer and develop new therapeutic approaches, surgeons on the front line of patient care are also working hard to improve outcomes.
Hari Nathan, M.D., Ph.D., an assistant professor of surgery at Michigan Medicine, explains.
Read moreThe National Pancreatic Foundation’s National Center of Excellence for Pancreatic Cancer designation is earned by hospitals that demonstrate the multi-disciplinary approach, social support and advanced research resources needed to treat this devastating disease.
Read more
A diagnosis of pancreatic or colon cancer often sparks dread about the disease’s likely next destination: the liver. That’s because liver metastasis is a leading cause of death in these patients. A Cedars-Sinai scientific team has been awarded a $9.1 million grant by the National Cancer Institute to study this often-fatal process, with the goal of understanding how cancer spreads to the liver and finding ways to block it.
Read moreHigh levels of CO2 in the body, due to chronic respiratory disorders, may exacerbate pancreatic cancer, making it more aggressive and resistant to therapy.
Read moreA multidisciplinary Michigan Medicine team is shedding new light on the role of regulatory T cells in pancreatic cancer — and, in mouse models, have uncovered a new potential target to improve immunotherapy approaches to the deadly disease.
Read moreThe University of Chicago Medicine’s Xavier Keutgen, MD, one of the few surgeons in the country with advanced expertise in extensive removal of neuroendocrine tumors, talks about this rare disease.
Read more
Researchers are still trying to find ways of catching pancreatic cancer early – or better yet, preventing it altogether. Meantime, here’s what patients need to know.
Read more
NCCN Guidelines for Genetic/Familial Risk Assessment: Breast, Ovarian, and Pancreatic updated with new and expanded sections on risk assessment and management related to three major cancer types.
Read more
Every day, more than 1200 people worldwide are told they have pancreatic cancer. Within 12 months, 80 per cent of them will have succumbed to the disease.
Read more
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice—supporting the immediate evaluation of the drugs in a clinical trial. U.S. Food and Drug Administration (FDA)–approved versions of the compounds are used today to treat certain leukemias and solid tumors, including melanoma. The study was published in Nature Cell Biology.
Read more
November is national Pancreatic Cancer Awareness month. This year alone, more than 56,000 Americans will be diagnosed with pancreatic cancer. Pancreatic tumors are particularly aggressive and hard to treat “due to a mutational profile that makes it resistant to therapies that work better for other tumor types,” explains Angela Alistar, MD, medical director of GI oncology at Morristown Medical Center. Dr. Alistar, an internationally known expert on pancreatic cancer, is now enrolling patients in five clinical trials aimed at pancreatic cancer.
Read moreNew research suggests a vaccine that blocks a digestive hormone may slow the spread of pancreatic cancer, potentially increasing survival rates. The study, published ahead of print in the American Journal of Physiology—Gastrointestinal and Liver Physiology, was chosen as an APSselect article for October.
Read more